NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Endevica Bio

Endevica Bio

Private
Northbrook, IllinoisHealthcare & Life Scienceshttps://www.endevicabio.com/

Last Round

Series B

Jan 19, 2023

Total Funding Raised

$16.27M

Company Overview

Endevica Bio is a biotechnology company that develops first-in-class peptide drug candidates for the treatment of cachexia caused by cancer and other chronic conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

peptide therapeuticscancer cachexiaGPCRG-protein coupled receptorsblood-brain barrierdrug discoverypeptidomimeticsai drug discoveryin silico drug designclinical-stage biotechmetabolic disordersbiotech startupcontract research organizationCRO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endevica Bio Comparables

Compare Endevica Bio with similar companies based on industry and business-model similarity.

Endevica Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kalohexis
85%
NGM Biopharmaceuticals
81%
Actimed Therapeutics
79%

Endevica Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 19, 2023
GrantJun 1, 2017
SeedJun 1, 2016

Key People

Founding team and executive leadership

Russell Potterfield

CEO And Executive Chairman

Executive Team

Endevica Bio Investors

Notable investors and investment history

Endevica Bio investors
InvestorRounds
Centennial InvestorsAngel, Seed, Series B
National Cancer InstituteGrant
Missouri Technology CorporationSeed, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 28, 2025

    Developing a peptide therapeutic drug to combat cachexia.

  • Apr 18, 2025

    Phase 2 trial initiated for B07, a cancer weight loss treatment.

Endevica Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endevica Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endevica Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNorthbrook, Illinois
Employee Range26
Year Founded2009
Last FundingJan 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.